2020
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma
Boulle G, Velut Y, Mansuet-Lupo A, Gibault L, Blons H, Fournel L, Boni A, Cremer I, Wislez M, Duchatelle V, Trédaniel J, Hammond S, Herbst R, Alifano M, Giraud P, Damotte D. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma. European Journal Of Cancer 2020, 135: 221-229. PMID: 32610210, DOI: 10.1016/j.ejca.2020.04.040.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overB7-H1 AntigenCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesChemoradiotherapyChemoradiotherapy, AdjuvantFemaleForkhead Transcription FactorsHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsTreatment OutcomeTumor MicroenvironmentConceptsT-cell densityCell lung carcinomaN2 NSCLCPatient survivalLung carcinomaClinical dataT cellsRadiotherapy efficacyIII-N2 NSCLCSurgery/chemotherapyPD-L1 expressionStandard of careImmunogenic cell deathDouble-positive cellsAction of radiotherapyIII-N2Immune environmentAbscopal effectChemoradiotherapy efficacyImmune infiltrationImmune cellsPositive cellsMultivariate analysisRadiotherapyTumor samples
2008
Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer
Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 351-357. PMID: 18379352, DOI: 10.1097/jto.0b013e318168c7e9.Peer-Reviewed Original ResearchConceptsLung cancer patientsTumor cavitationCancer patientsAntiangiogenesis agentsAdverse eventsLung cancerMD Anderson Cancer CenterChest imaging findingsProgression-free survivalAdditional adverse eventsSquamous cell histologySquamous cell tumorsAnderson Cancer CenterCavitary tumorsPrevious chemotherapyCell histologyOverall survivalClinical outcomesImaging findingsCancer CenterCell tumorsTumor locationMedical recordsClinical dataClinical significanceMultitargeted Inhibitors in Lung Cancer: New Clinical Data
Bar J, Herbst RS, Onn A. Multitargeted Inhibitors in Lung Cancer: New Clinical Data. Clinical Lung Cancer 2008, 9: s92-s99. PMID: 19419930, DOI: 10.3816/clc.2008.s.014.Peer-Reviewed Original ResearchConceptsLung cancerManagement of patientsCell lung cancerOngoing clinical trialsNew clinical dataCombination of therapiesTreatment arsenalMultitargeted therapyClinical trialsNovel therapiesClinical dataNovel agentsRadiation therapyTraditional chemotherapyTherapyCancerClinical useMalignant growthMultitargeted inhibitorsTreatmentPathwayMajor pathwayChemotherapyPatientsAgents
2007
Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients
Onn A, Martinez C, Herbst R, Riddle J, Blumenschein G, Stewart D, Marom E. Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients. Journal Of Clinical Oncology 2007, 25: 18034-18034. DOI: 10.1200/jco.2007.25.18_suppl.18034.Peer-Reviewed Original ResearchTumor cavitationLung cancer patientsAntiangiogenic agentsCancer patientsAngiogenesis inhibitorsNon-small cell lung cancer patientsClinical implicationsMedian progression-free survivalCell lung cancer patientsMD Anderson Cancer CenterProgression-free survivalSoft tissue densityAnderson Cancer CenterPrevious chemotherapyStable diseaseAdverse eventsNSCLC patientsAdvanced cancerCancer CenterNSCLC casesLung cancerPrimary tumorMedical recordsSubsegmental arteriesClinical data
2004
Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology 2004, 18: 54-62. PMID: 15339061.Peer-Reviewed Original ResearchConceptsAdvanced NSCLCConcurrent chest radiationPhase II studySecond-line therapyPhase III trialsCell lung cancerFavorable toxicity profileTreatment of mesotheliomaChest radiationII studyIII trialsSystemic dosesThoracic malignanciesFrontline settingLung cancerClinical dataToxicity profilePlatinum agentsSide effectsUS FoodDrug AdministrationPhase IPemetrexedNSCLCNovel mechanismPemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of the Clinical Data
Zinner RG, Herbst RS. Pemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of the Clinical Data. Clinical Lung Cancer 2004, 5: s67-s74. PMID: 15117428, DOI: 10.3816/clc.2004.s.006.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSecond-line activityPhase III trialsIII trialsLung cancerAdvanced non-small cell lung cancerPhase II studyFirst-line therapyCell lung cancerFavorable toxicity profileChest radiationII studyThoracic malignanciesClinical dataSignificant efficacyToxicity profileSide effectsUseful agentFDA approvalPemetrexedPhase ICisplatinTrialsFurther studiesMesothelioma
2003
Surrogate markers in antiangiogenesis clinical trials
Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. British Journal Of Cancer 2003, 89: 8-14. PMID: 12838293, PMCID: PMC2394225, DOI: 10.1038/sj.bjc.6601035.Peer-Reviewed Original Research
2002
ZD1839 (Iressa™) in Non-Small Cell Lung Cancer
Herbst RS, Kies MS. ZD1839 (Iressa™) in Non-Small Cell Lung Cancer. The Oncologist 2002, 7: 9-15. PMID: 12202783, DOI: 10.1634/theoncologist.7-suppl_4-9.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerAdvanced non-small cell lung cancerEGFR tyrosine kinase inhibitor ZD1839Treatment of NSCLCCisplatin-based combination chemotherapyAnti-EGFR agentsConventional cytotoxic chemotherapyAvailable clinical dataGrowth factor receptorCombination chemotherapyCytotoxic chemotherapyPatient populationClinical dataClinical developmentGreater efficacyFactor receptorZD1839Less toxicityUseful targetChemotherapyCancerPrognosis